Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Fundamental Analysis

NASDAQ:INKT - Nasdaq - US6036932019 - Common Stock - Currency: USD

7.59  +0.01 (+0.16%)

Fundamental Rating

0

Overall INKT gets a fundamental rating of 0 out of 10. We evaluated INKT against 559 industry peers in the Biotechnology industry. Both the profitability and financial health of INKT have multiple concerns. INKT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INKT had negative earnings in the past year.
In the past year INKT has reported a negative cash flow from operations.
In the past 5 years INKT always reported negative net income.
In the past 5 years INKT always reported negative operating cash flow.
INKT Yearly Net Income VS EBIT VS OCF VS FCFINKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -228.21%, INKT is not doing good in the industry: 91.06% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -228.21%
ROE N/A
ROIC N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INKT Yearly ROA, ROE, ROICINKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INKT Yearly Profit, Operating, Gross MarginsINKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, INKT has more shares outstanding
INKT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INKT has a worse debt to assets ratio.
INKT Yearly Shares OutstandingINKT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
INKT Yearly Total Debt VS Total AssetsINKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

INKT has an Altman-Z score of -57.77. This is a bad value and indicates that INKT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -57.77, INKT is not doing good in the industry: 94.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -57.77
ROIC/WACCN/A
WACCN/A
INKT Yearly LT Debt VS Equity VS FCFINKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

INKT has a Current Ratio of 0.30. This is a bad value and indicates that INKT is not financially healthy enough and could expect problems in meeting its short term obligations.
INKT's Current ratio of 0.30 is on the low side compared to the rest of the industry. INKT is outperformed by 94.28% of its industry peers.
A Quick Ratio of 0.30 indicates that INKT may have some problems paying its short term obligations.
INKT has a Quick ratio of 0.30. This is amonst the worse of the industry: INKT underperforms 93.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.3
INKT Yearly Current Assets VS Current LiabilitesINKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

INKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.00%, which is quite impressive.
EPS 1Y (TTM)58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INKT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.59%
EPS Next 2Y30.24%
EPS Next 3Y19.7%
EPS Next 5Y9.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INKT Yearly Revenue VS EstimatesINKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2028 2029 2030 20M 40M 60M 80M
INKT Yearly EPS VS EstimatesINKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INKT Price Earnings VS Forward Price EarningsINKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INKT Per share dataINKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

INKT's earnings are expected to grow with 19.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.24%
EPS Next 3Y19.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINK THERAPEUTICS INC

NASDAQ:INKT (6/11/2025, 8:00:02 PM)

7.59

+0.01 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners2.09%
Inst Owner Change-91.17%
Ins Owners7.95%
Ins Owner Change0.08%
Market Cap30.28M
Analysts84.44
Price Target35.7 (370.36%)
Short Float %2.13%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.04%
Min EPS beat(2)-21.57%
Max EPS beat(2)-12.5%
EPS beat(4)2
Avg EPS beat(4)9.01%
Min EPS beat(4)-21.57%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)11.68%
EPS beat(12)8
Avg EPS beat(12)13.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.59%
PT rev (3m)-27.59%
EPS NQ rev (1m)27.81%
EPS NQ rev (3m)30.77%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.52
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS-5.46
TBVpS-5.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -228.21%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.3
Altman-Z -57.77
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.6%
Cap/Depr(5y)359.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y43.59%
EPS Next 2Y30.24%
EPS Next 3Y19.7%
EPS Next 5Y9.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.83%
OCF growth 3YN/A
OCF growth 5YN/A